Sign inJoin waitlistJoin the waitlist

Ari Baron

Department Chair, Hematology/Oncology · Sutter Health

Credentials: · · ·

History

Hematology/Oncology Department · Sutter Health
Present

University of California-San Francisco
1993–1995
Internal Medicine
1990–1993
Tufts University School of Medicine
1986–1990

Research

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
New England Journal of Medicine · 2004 · 8,376 citations
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
The Lancet · 2018 · 4,649 citations
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
The Lancet Oncology · 2017 · 1,336 citations

AZ
Andrew Zhu
5 papers
Anthony El-Khoueiry
5 papers
KM
Kalgi Mody
4 papers
Max Sung
4 papers
Richard Finn
4 papers
AS
Abby Siegel
3 papers
PA
Paolo Abada
3 papers
Amit Mahipal
2 papers
CH
Celestia Higano
2 papers
DM
Daniel Maslyar
2 papers
Eric Small
2 papers
GA
Ghassan Abou-Alfa
2 papers

Clinical trials

Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers
Principal investigator · Terminated · Phase 2
New Mexico Cancer Research Alliance
2007–2017
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2024–2028
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2024–2028
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2023–2028